Apollo’s sharp rally is backed by improving earnings, but expectations are already demanding
Price
₹9,200
Day change
+5.29%
P/E
76.14
ROE
12.18%
Apollo Hospitals closed at ₹9,200, up on the latest session in the quote data; the market is closed, so this is not a live intraday price. The rally fits the story’s sector-wide optimism, and Apollo’s latest annual results show stronger profit growth and margins. But its elevated valuation means the move raises the importance of checking whether growth and hospital expansion can continue to justify the premium.
5.29%
Price action and trend
The supplied story reports hospital shares rising as much as 14% over five sessions; it gives Apollo’s BSE close as ₹9,190.05, while the latest quote tool reports an NSE close of ₹9,200.
The one-month chart shows Apollo up 18.71%, from ₹7,750 to ₹9,200, with a period high of ₹9,282.50. The latest close is near that high, following a strong advance.
Chart levels from the tool: ₹8,786.50 resistance and ₹8,176 support. These are technical reference points, not guaranteed barriers; a sustained move above the recent high would show the advance holding, while a retreat toward support would test how much of the rally persists.
The data labels the one-month trend “neutral” despite the strong percentage rise. That is a reminder not to treat recent momentum alone as confirmation of a durable trend.
Fundamentals: growth is improving; valuation leaves less room for disappointment
Apollo’s consolidated annual results show revenue of ₹24,960.7 crore in March 2026, up 13.49%, and net profit of ₹2,002.7 crore, up 33.06%. Operating margin increased to 10.70% from 9.27% a year earlier. The four-period revenue and net-profit CAGRs are 14.33% and 33.36%, respectively.
Cash generation was positive: operating cash flow was ₹2,855.7 crore and free cash flow ₹707.5 crore in March 2026. On the balance sheet, total liabilities were 55.06% of assets, down from 58.11% in March 2025; net worth was ₹9,974.5 crore. This suggests improving leverage relative to the prior year, although the liabilities-to-assets measure is not a substitute for a detailed look at debt and lease obligations.
Valuation is the main counterweight. Fundamentals data reports P/E 56.53, P/B 12.46 and EV/EBITDA 29.71, each above the corresponding sector figure supplied by the tool. The live quote separately reports a P/E of 53.75; ratios can differ by source, timing or calculation basis. Either way, the broad signal is that the shares are priced richly, so continued earnings delivery matters.
Ownership and peer context
Promoter holding was unchanged at 28.02% in September 2026. FII ownership rose 1.68 percentage points from the prior quarter to 43.18%, while other DII ownership fell 1.51 points to 4.88%; mutual funds edged down 0.14 points to 17.19%. These are quarter-to-quarter changes, not proof of why investors traded.
Against Fortis, Apollo’s reported P/E is slightly lower (56.53 vs 58.64) but its P/B is much higher (12.46 vs 5.94). Apollo’s returns on assets, equity and capital employed are also higher in the supplied comparison; Fortis has a higher latest net margin (11.59% vs 8.02%). Apollo’s latest annual free cash flow was larger in absolute terms (₹707.5 crore vs ₹63.05 crore), though company scale differs. Max Healthcare also trades at a substantial valuation in the available snapshot: P/E 76.14 and EV/EBITDA 40.49. These ratios are not directly comparable without accounting for growth, business mix and period differences.
Options context
Apollo appears in the F&O data. The chain is for the 23 November 2026 expiry, with spot at ₹9,200, put-call ratio 0.66, and reported max pain ₹8,400. Near-spot option activity is concentrated around the ₹9,000–₹9,300 strikes, but the chain’s max-pain figure is well below spot and open interest is relatively small in the supplied data. Treat these as limited positioning clues, not reliable price targets or standalone directional evidence. The market is closed, and the expiry is imminent, so liquidity and rapid time decay are especially relevant.
What to watch
Whether Apollo sustains trade above the recent ₹9,282.50 chart high, or falls back toward the chart’s ₹8,786.50 and ₹8,176 reference levels.
Upcoming results for continued bed additions, occupancy, pricing, margin improvement and cash conversion—the factors that could support the earnings-growth story.
Valuation against earnings delivery: the premium multiples heighten sensitivity to any slowdown or cost pressure.
Follow-up changes in FII, mutual-fund and other DII ownership.
Near-expiry option positioning with caution: the chain is a short-dated snapshot, and its indicators can shift quickly.
Bottom line: The rally coincides with genuine improvement in Apollo’s reported profit, margins and cash generation, but the valuation premium is material. Whether the advance holds depends on continued operating delivery, not the sector rally alone.
The data behind this
What edge looked up while writing this, as of the time above.
Max Healthcare Institute Limited is an India-based integrated healthcare provider. The Company operates through a single segment, namely Medical and Healthcare Services. It provides a wide array of services, including advanced cardiac care, lung transplants, prostate laser surgery, orthopedics, oncology, neurosciences, transplants, minimal access metabolic and bariatric surgery, and other services, including obstetrics and gynecology, pediatrics and nephrology. The Company also provides outpatient services, including consultations for a range of ailments, preventive health screenings, and laboratory services, as well as radiology, imaging, and emergency services. The Company has two strategic business units (SBUs): Max Lab and Max@Home. The Company owns and operates approximately 22 healthcare facilities across the Delhi NCR, Haryana, Punjab, Uttarakhand, Maharashtra, and Uttar Pradesh. It also offers diagnostic services to patients outside its network.
Price
Rs 1,081
Day change
+3.88%
Day range
1,050.05 - 1,090
Volume
95.3L
P/E
76.14 (sector 55.28)
P/B
9.27 (sector 3.05)
ROA
7.37% (sector 4.2%)
ROE
12.18% (sector -31.98%)
ROCE
13.24% (sector 11.89%)
Quick Ratio
0.84 (sector 32.98)
EV/EBITDA
40.49 (sector 23.22)
Pros
ROA at 9.65% vs sector 4.2% (better than sector)
ROE at 21.14% vs sector -31.98% (better than sector)
ROCE at 18.94% vs sector 11.89% (better than sector)
Revenue CAGR 14.33% across 4 annual periods
Net profit CAGR 33.36% across 4 annual periods
Operating margin 10.70% in Mar 2026 vs 9.27% in Mar 2025
Concerns
P/E at 56.53 vs sector 55.28 (worse than sector)
P/B at 12.46 vs sector 3.05 (worse than sector)
Quick Ratio at 0.98 vs sector 32.98 (worse than sector)
EV/EBITDA at 29.71 vs sector 23.22 (worse than sector)
DII (other) holding 4.88% in Sep 2026 (-1.51 pts)
Fundamentals Profit Loss4 items
Fundamentals Profit Loss results
Period
Revenue
Operating Profit
Net Profit
Revenue Change Percent
Net Profit Change Percent
Mar 2026
24,960.7
2,671.7
2,002.7
13.49
33.06
Mar 2025
21,994.3
2,039.1
1,505.1
14.76
60.97
Mar 2024
19,165.5
1,380.5
935
14.74
10.74
Mar 2023
16,702.8
1,100.5
844.3
-
-
Fundamentals Balance Sheet4 items
Fundamentals Balance Sheet results
Asset Growth Percent
Liabilities To Assets Percent
Period
Total Assets
Total Liabilities
Net Worth
7.45
55.06
Mar 2026
22,196.9
12,222.4
9,974.5
23.3
58.11
Mar 2025
20,657.4
12,004.5
8,652.9
16.12
56.3
Mar 2024
16,753.1
9,432.6
7,320.5
-
54.73
Mar 2023
14,427.8
7,896.5
6,531.3
Fundamentals Shareholding5 items
Fundamentals Shareholding results
Category
Label
Latest
Previous
Delta Percent Points
History
promoters
Promoters
28.02
28.02
0
4 items
fii
FII
43.18
41.5
1.68
4 items
other_dii
DII (other)
4.88
6.39
-1.51
4 items
retail_and_other
Retail & others
6.72
6.77
-0.05
4 items
mutual_funds
Mutual funds
17.19
17.33
-0.14
4 items
Fundamental comparison
Apollo Hospitals
APOLLOHOSP · Healthcare Services
Price Rs 9,200Revenue CAGR +14.3%Net margin +8.0%
Fortis Healthcare
FORTIS · Healthcare Services
Price Rs 825Revenue CAGR +13.0%Net margin +11.6%
Metric
APOLLOHOSP
FORTIS
Current Price
9,200
825
Day Change
5.29%
1.87%
P/E
56.53
58.64
P/B
12.46
5.94
ROA
9.65%
6.47%
ROE
21.14%
9.91%
ROCE
18.94%
12.56%
Quick Ratio
0.98
0.8
EV/EBITDA
29.71
28.99
Revenue CAGR
14.33%
13.01%
Net Profit CAGR
33.36%
18.91%
Latest Net Margin
8.02%
11.59%
Latest Free Cash Flow
707.5
63.05
Promoter Holding
28.02%
31.17%
Fundamentals Peers10 items
Fundamentals Peers results
Change Percent
Volume
Symbol
Sector
Market Cap Inr Crore
Market Cap Display
3.88
95,31,767
MAXHEALTH
Healthcare Services
1,05,080.39
105,080.39 Cr
0.83
11,61,682
MANIPALHOS
Healthcare
92,365.79
92,365.79 Cr
5.41
26,65,994
ASTERDM
Healthcare Services
67,959.94
67,959.94 Cr
1.87
22,88,213
FORTIS
Healthcare Services
62,284.05
62,284.05 Cr
0.13
2,65,365
MEDANTA
Healthcare Services
39,828.83
39,828.83 Cr
3.84
7,84,702
NH
Healthcare Services
39,757.37
39,757.37 Cr
1.31
2,64,951
LALPATHLAB
Healthcare Services
33,679.7
33,679.70 Cr
3.62
10,43,606
KIMS
Healthcare Services
33,482.92
33,482.92 Cr
3.28
25,57,651
SYNGENE
Diversified
18,239.79
18,239.79 Cr
-2.02
7,00,865
MOLBIO
Healthcare
17,228.38
17,228.38 Cr
Written by snipy edge, an AI market analyst, from the story above and live market data at the time shown. For information only. This is not investment advice or a recommendation to buy or sell any security.